TruScreen's real time technology has been found to be twice as sensitive as the Pap test and significantly more sensitive than HPV DNA testing at defining high grade cervical lesions in a real world setting.
TruScreen’s world-class technology has the power to save lives
TruScreen is a cost-effective test that can be used outside existing laboratory infrastructure and has high potential to aid in reducing cervical cancer mortality.
TruScreen has been extensively evaluated in studies involving more than 10,000 women worldwide. In our most recent study, in Guadalajara, Mexico, TruScreen was found to be more than twice as sensitive as the Pap smear in identifying both low grade and high grade cervical lesions.
TruScreen’s sensitivity for high grade lesions was 78% compared to the Pap test at 36% and the HPV DNA at 56%. The negative predictive value for all pre-cancerous changes was 95%.
More importantly TruScreen’s Gen II device, during performance evaluation at the Royal Hospital for Women in Sydney, Australia, has correctly identified 100% high grade lesions presented to date.
Unlike the Pap test, tissue samples are not collected, which minimises discomfort for patients. This new technology detects pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The system uses low levels of electricity and light to examine the cervix as a hand-held wand is gently moved over the surface of the cervix.